Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05180786 · ClinicalTrials.gov registry record · NA

Error-enhanced Learning & Recovery in 2 & 3 Dimensions

A NA study of Stroke and Cerebral Vascular Accident (CVA)/Stroke, sponsored by Shirley Ryan AbilityLab.

Recruiting
Registry status
NA
Development phase
20
Enrollment target
3
Study locations

NCT05180786: Recruiting NA study of Stroke and Cerebral Vascular Accident (CVA)/Stroke, sponsored by Shirley Ryan AbilityLab.

NCT05180786 is a NA study of Stroke and Cerebral Vascular Accident (CVA)/Stroke that is actively recruiting participants, run by Shirley Ryan AbilityLab. The registered enrollment target is 20 participants, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (100% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05180786, a NA study of Stroke and Cerebral Vascular Accident (CVA)/Stroke, is actively recruiting participants, sponsored by Shirley Ryan AbilityLab.

RECRUITING
Registry status
NA
Development phase
20 participants
Enrollment target
3
Study locations

Study Summary

This study is being done to see how errors lead to improvement. Specifically, we are evaluating the errors stroke participants make during an upper extremity exercise program when reaching for a target using their affected arm. Once we understand the participant's reaching errors, we plan to create a customized reaching exercise according to the individual's specific error tendencies which will lead to better performance on movement ability after training.

Interventions

  • OTHER Error Fields
  • OTHER No Error Fields

Study Locations (3)

Illinois

  • Shirley Ryan AbilityLab (Healthy Participants) - Chicago
  • Shirley Ryan AbilityLab - Chicago
  • Shirley Ryan AbilityLab - Chicago

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2023-03-01
Est. Completion 2025-12-30
Phase NA
Shirley Ryan AbilityLab

138 total trials

What NCT05180786 shows while recruiting

NCT05180786 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (100% lower).

The record links to 2 conditions, with Stroke appearing as the primary indexed condition, and to 2 interventions - of which Error Fields is the first listed.

NCT05180786 reports a single indexed study location in Illinois.

Frequently Asked Questions

What is clinical trial NCT05180786 about?

NCT05180786 is a clinical study titled "Error-enhanced Learning & Recovery in 2 & 3 Dimensions". This study is being done to see how errors lead to improvement. Specifically, we are evaluating the errors stroke participants make during an upper extremity exercise program when reaching for a target using their affected arm. Once we understand the participant's reaching errors, we plan to create ...

What is the current status of trial NCT05180786?

This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2023-03-01. Estimated completion is 2025-12-30.

What conditions does trial NCT05180786 study?

This clinical trial studies the following conditions: Stroke, Cerebral Vascular Accident (CVA)/Stroke.

What interventions are being tested in trial NCT05180786?

The interventions under investigation include: Error Fields (OTHER), No Error Fields (OTHER).

Who is sponsoring clinical trial NCT05180786?

This trial is sponsored by Shirley Ryan AbilityLab, which has 138 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05180786 being conducted?

This trial has 3 study locations across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Stroke

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05180786's enrollment target sits among peer trials

20 361st of 454 higher than 74 of 454 other Stroke trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Stroke trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05180786, the US trial registry maintained by the National Library of Medicine. NCT05180786 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.